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The molecular mechanisms underlying congenital long QT syndrome (LQTS) are now beginning to be
understood. New insights into the etiology and therapeutic strategies are emerging from heterologous
expression studies of LQTS-linked mutant proteins, as well as inducible pluripotent stem cell derived
cardiomyocytes (iPSC-CMs) from LQTS patients. This review focuses on the major molecular mechanism
that underlies LQTS type 2 (LQT2). LQT2 is caused by loss of function (LOF) mutations in KCNH2 (also
known as the human Ether-à-go-go-Related Gene or hERG). Most LQT2-linked mutations are missense
mutations and functional studies suggest that 90% of them disrupt the intracellular transport (traf-
ﬁcking) of KCNH2-encoded Kv11.1 proteins to the cell membrane. Trafﬁcking deﬁcient LQT2 mutations
disrupt Kv11.1 protein folding and misfolded Kv11.1 proteins are retained in the endoplasmic reticulum
(ER) until they are degraded in the ER associated degradation pathway (ERAD). This review focuses on
the quality control mechanisms in the ER that contribute to the folding and ERAD of Kv11.1 proteins; the
mechanism for ER export of Kv11.1 proteins in the secretory pathway; different subclasses of trafﬁcking
deﬁcient LQT2 mutations; and strategies being developed to mitigate or correct trafﬁcking deﬁcient
LQT2-related phenotypes.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
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1.1. Congenital long QT syndrome
Long QT syndrome (LQTS) is a condition characterized by
delayed ventricular and atrial repolarization, prolongation of the
QT interval on an electrocardiogram (ECG), and an increased risk
for the potentially fatal tachyarrhythmia Torsades de Pointes [1].
The ﬁrst description of congenital LQTS probably dates back to Dr.
Friedrich Ludwig Meissner's account of a deaf schoolgirl who died
suddenly while being publically scolded in 1856 (Fig. 1) (http://
www.qtsyndrome.ch/history.html). A century later, autosomal
dominant LQTS (Romano-Ward Syndrome) was described as the
major variant and a phenotypic diagnostic score based on patient
ECG characteristics, symptoms, and family history was developed
[2]. In the decades that followed, genetic mutations in cardiac ion
channel related genes, as well as an increasing number of drugs,
have been recognized to cause LQTS. Additionally, the major
monogenic causes of congenital LQTS were identiﬁed: KCNQ1
(LQT1), KCNH2 (LQT2), and SCN5A (LQT3) [3–9]. LQT1–LQT3 make
up 90% of the genetically conﬁrmed cases, and each type has
distinct triggers, penetrance, and responsiveness to therapy [10].
Genetic testing for LQTS is commercially available and a genotype
positive test for an unequivocal pathogenic LQTS mutation inﬂu-
ences important clinical decisions [11].
1.2. Kv11.1 and the long QT syndrome type 2
KCNH2 (also known as the human Ether-à-go-go-Related Gene or
hERG) encodes the voltage-gated Kþ (Kv) channel α-subunit Kv11.1.
Four Kv11.1 α-subunits co-assemble into a tetrameric ion channel
that conducts the rapidly activating delayed rectiﬁer Kþ current (IKr)
in the heart [4,7]. Loss-of-function (LOF) KCNH2 mutations decrease
IKr in type 2 LQTS (LQT2) [7,12,13]. The extent by which IKr is
impacted in LQT2 is mutation-speciﬁc. It ranges from a small
reduction in IKr to a nearly complete loss in IKr, Haploinsufﬁcient
mutations results in a LOF of the affected allele, whereas dominant
negative (DN) mutations cause a LOF in the affected allele and
negatively impact the function of the Kv11.1 proteins encoded by the
normal or wild type (WT) allele. The QT interval is a reﬂection of the
ventricular action potential (AP) duration. For didactic purposes, we
performed computational AP simulations to show the impact that a1980 19901960
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Fig. 1. A historical timeline of clinically relevant events30% or 70% reduction in IKr has on the steady-state AP duration at
different cycle lengths (Fig. 2) [14]. The prolongation in the AP
duration is much more severe for the simulations with the 70%
reduction in IKr. Consistent with this result, DN LQT2 mutations
located in the pore region are linked to an increased risk for
arrhythmic events in patients [15].
The mechanisms by which KCNH2 mutations cause a LOF is
understood in terms of the biophysical components that underlie
macroscopic current (I) [16]. By deﬁnition, I is a product of the number
of channels expressed in the cell membrane (n), channel open prob-
ability (Po), and the amplitude of the single channel current (i), so that
I¼(n) (Po) (i) [17]. A LOF in one of these biophysical components
can be used to classify LQT2-linked Kv11.1 mutations. Class 1 muta-
tions disrupt the synthesis/translation of Kv11.1 α-subunits (decrease
n); Class 2 mutations reduce the intracellular transport or trafﬁcking of
Kv11.1 proteins to the cell membrane (decrease n); Class 3 mutations
disrupt Kv11.1 channel gating (decrease Po); and Class 4 mutations
negatively affect Kþ permeation (decrease i).
About 40% of LQT2-linked KCNH2 mutations are nonsense
mutations, frameshift mutations, insertions, deletions, duplications,
or involve a splice site that inhibits Kv11.1 protein synthesis/trans-
lation by generating incomplete proteins or causing nonsense-
mediated RNA decay (NMD) (class 1 mechanism) [18–20]. By pro-
voking NMD, class 1 mutations are expected to cause haploinsufﬁ-
ciency. The remaining 60% of LQT2 mutations are missense, where
a single nucleotide change alters an amino acid codon to a different
amino acid to cause a LOF by disrupting channel trafﬁcking to the cell
membrane (class 2 mechanism), gating (class 3 mechanism), and/or
single channel current (class 4 mechanism) [16,20–27]. Over 150
suspected LQT2-causing missense mutations have been studied using
heterologous expression systems and these studies demonstrate that
90% of LQT2-linked missense mutations disrupt Kv11.1 channel
function via a class 2 mechanism (Fig. 3) [20–28]. Class 2 LQT2
mutations decrease the folding efﬁciency of Kv11.1 proteins and
increase their retention in the endoplasmic reticulum (ER) by cellular
quality control mechanisms.
This review focuses on the molecular mechanisms of the class
2 LQT2 phenotype. We summarize several ﬁndings for the reg-
ulation of WT Kv11.1 protein trafﬁcking early in the secretory
pathway. We also summarize the ﬁndings of several studies that
investigate trafﬁcking deﬁcient LQT2-causing mutations.2007: 
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Fig. 2. Mutation-speciﬁc differences in IKr differentially affect ventricular APs. Computational simulations of the membrane voltage (Vm) results, using the Soltis–Saucerman
rabbit ventricular myocyte AP model, are illustrated for normal conditions (37 °C and 5.4 mM extracellular [Kþ], black traces) as well as following reduction in IKr by 30%
(blue traces) or by 70% (red traces). Dashed lines represent 0 mV or 0 pA levels in Vm and IKr recordings, respectively. The duration of the steady-state ventricular AP at 90%
repolarization (APD90) is plotted as a function of cycle length to predict the absolute changes at different heart rates.
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Fig. 3. Most LOF LQT2-linked missense mutations are trafﬁcking deﬁcient. The
diagram illustrates a Kv11.1a α-subunit with an intracellular NH2 terminus (N1), six
transmembrane segments (S1–S6), and the COOH terminus (C1159). The relative
locations of different LQT2 Kv11.1a missense mutations are shown. Mutations that
primarily disrupt Kv11.1a trafﬁcking, gating, and ion permeation are shown by
black, red, and blue circles, respectively. Functionally normal variants are shown by
white circles. Most of the trafﬁcking deﬁcient mutations are located in the Per-
Arnt-Sim domain (PASD) in the N-terminus, pore domain (S5–S6), or the cyclic
nucleotide-binding domain (CNBD) in the COOH-terminus. Dashed boxes indicate
the location of PASD and CNBD domains. See the study by Anderson and colleagues
(2014) for speciﬁc details [28].
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2.1. Kþ channel biogenesis
A single Kv α-subunit contains cytosolic amino (NH2) and car-
boxy (COOH) termini and six α-helical transmembrane segments
(S1–S6; Fig. 3) [17]. Electron density maps of crystalized Kv
channels suggest that each α-subunit has a voltage-sensor domain
formed by S1–S4 and a pore domain formed by S5 and S6 [29]. The
sequence of events during Kv channel biogenesis (based on pre-
vious ﬁndings investigating Shaker Kþ channels) consists of the
following steps: (1) membrane insertion and asparagine-linked
(N-linked) “core” glycosylation, (2) oligomerization of α- and
auxiliary subunits, (3) formation of the voltage-sensor and poredomains, and (4) juxtapositioning of adjacent amino (NH2) and
carboxy (COOH) termini [30]. A series of elegant studies demon-
strate that Kv α-subunit secondary structures, including the tet-
ramerization domain and transmembrane segments of the voltage
sensor, begin to form inside the ribosomal tunnel during transla-
tion [31–36]. Even the S3–S4 hairpin “paddle” of the voltage-
sensor forms near the exit of the ribosome tunnel [35]. These
preformed secondary structures probably inﬂuence subsequent
tertiary folding, timing and efﬁciency of membrane insertion
events, and subunit co-assembly [32,36]. Therefore, it is not sur-
prising that a single amino acid missense mutation can increase
the probability of channel protein misfolding. Consistent with this
concept, most class 2 LQT2 mutations localize to the highly
structured regions in the Kv11.1a α-subunit, including the Per-
Arnt-Sim domain (PASD) in the NH2 terminus, the pore domain,
and the cyclic nucleotide-binding domain (CNBD) in the COOH
terminus (Fig. 3).
2.2. Kv11.1: assembly required
The IKr channel is a tetramer of KCNH2 gene products and the
KCNE2 encoded MiRP1 auxiliary subunit. MiRP1 is a single trans-
membrane spanning peptide that modiﬁes Kv11.1 channel gating
and associates with several other ion channels in the heart [37,38].
Most studies that investigate drug block of IKr or LQT2 mutations
focus on the full-length, 15-exon, 1159 amino acid Kv11.1a α-
subunit (hERG1a or KCNH2a; Fig. 3). A second KCNH2 gene pro-
duct, the Kv11.1b α-subunit, is generated from an alternative start
site on the 5' exon that reduces the protein size by deleting exons
1–5 (hERG1b or KCNH2b) [39]. Alternative splicing and poly-
adenylation of pre-mRNA can generate truncated versions of
Kv11.1a and Kv11.1b transcripts (Kv11.1a-USO or Kv11.1b-USO) but
these gene products are not functional [40,41]. Kv11.1a is the key
functional α-subunit because Kv11.1b proteins are retained in the
endoplasmic reticulum (ER) unless they heterotetramerize with
Kv11.1a proteins [42].
2.3. Chaperones facilitate Kv11.1a folding and degradation
The ER is a reticular network that extends from the nucleus to
the cell periphery. It contains a variety of domains and compart-
ments that participate in the biosynthesis of proteins and lipids,
Ca2þ storage, apoptosis signaling, cellular quality control, ER-
associated degradation (ERAD), and ER export. The environment
in the ER optimizes nascent protein folding, assembly, and
Fig. 4. A simpliﬁed illustration of the regulation of Kv11.1a protein folding and
ERAD by cytosolic chaperones. Several studies suggest that Hsp40 activates Hsc70
and CHIP to facilitate ubiquitination/ERAD of Kv11.1a protein (left). Ubiquitinated
Kv11.1a protein is transported into the cytosol via the translocon, where it is
degraded by the proteasome. In contrast, Hsp70, HOP, and Hsp90 play a reciprocal
role promoting native folding of Kv11.1a proteins and export them via transitional
ER elements called ER exit sites (ERES, right).
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trafﬁcking of misfolded or incompletely assembled proteins to
their target membranes [43]. Some proteins fold efﬁciently into
their correct or “native” conﬁguration but others do not. Molecular
chaperone proteins in the ER or cytoplasm interact with nascent
proteins to facilitate the folding process or target misfolded pro-
teins in the ERAD pathway (Fig. 4).
Several different chaperone and co-chaperone proteins that
interact with Kv11.1a proteins have been identiﬁed. They include
the ER lectin chaperone calnexin, the ER transmembrane chaper-
one 38-kDa FK506-binding protein FKBP8 (FKBP38), cytosolic heat
shock proteins 40, 70, and 90 (Hsp40, Hsp70, and Hsp90), the
cytosolic heat shock cognate protein 70 (Hsc70), the cytosolic co-
chaperone Hsp-organizing protein (HOP), the BCL-associated
athanogene 2 (BAG-2), and the E3-ubiquitin ligase CHIP [44–46].
Ficker and colleagues (2002) were the ﬁrst to demonstrate that
Hsp90 is crucial for the maturation and trafﬁcking of Kv11.1a
channels to the cell membrane [44]. Unlike Hsp70 or Hsc70, which
bind to most newly synthesized proteins, Hsp90 facilitates the
folding for only a subset of speciﬁc proteins. Pharmacological
inhibition of Hsp90 increases the ER retention and ERAD of Kv11.1a
proteins. Iwai and colleagues (2013) show that Hsp90 expression
increases the stability of Kv11.1a proteins by decreasing CHIP-
mediated degradation in the ERAD pathway (Fig. 4, right) [47].
The Hsp90 co-chaperone FKBP38 is also important for Kv11.1a
channel protein stability. Walker and colleagues (2008) found that
knocking down FKBP38 expression levels negatively affects
Kv11.1a channel protein trafﬁcking early in the secretory pathway
[45]. In another study, Walker and colleagues (2010) show that the
expression of different Hsp40 co-chaperones activate Hsc70 to
destabilize Kv11.1a proteins by increasing CHIP-mediated ERAD
(Fig. 4; left) [48]. Li and colleagues (2011) found that expression of
Hsp70 exerts the opposite effect of Hsc70 and increases Kv11.1a
protein stability [43]. Based on these studies, a simpliﬁed model of
the cytosolic chaperone/co-chaperone network that regulates the
stability and trafﬁcking of Kv11.1a proteins is provided in Fig. 4.
Hsp40/Hsc70/CHIP facilitate the ubiquitination and ERAD of
Kv11.1a proteins, and Kv11.1a proteins are transported to the
cytosol through the translocon and then degraded by the protea-
some. Alternatively, Hsp70 couples to Hsp90 (presumably via
HOP) to prevent the ERAD of Kv11.1a proteins by CHIP and pro-
mote their native folding (Fig. 4, right).
Calnexin plays an important role in the biogenesis and quality
control of N-linked glycoproteins [49]. It interacts with glycanmoieties of newly synthesized glycoproteins until they are prop-
erly folded. If the glycoproteins fail to fold correctly, calnexin in
conjunction with calreticulin can lead to their retention in the ER.
Although the Kv11.1a α-subunit is synthesized in the ER as a
135 kDa N-linked glycoprotein, the role that calnexin/calreticu-
lin have in the ER retention of Kv11.1a is not clear [24,50]. N-linked
glycosylation was initially thought to be obligatory for the ER
export of Kv11.1a [51], but more recent studies show glycosylation-
deﬁcient Kv11.1a channels readily trafﬁc to the cell membrane
[52].
2.4. ER export
Once a protein achieves its native conﬁguration, it is exported
from the ER in transitional ER elements called ER exit sites (ERES).
The small GTPase SAR1 initiates the polymerization of coat-
associated protein II (COPII)-associated proteins at ERES [53,54].
As COPII transport vesicles pinch off of the ERES, GTPase-activating
proteins (GAPs) hydrolyze GTP to GDP and SAR1 dissociates from
the vesicle and the COPII vesicles mediate the trafﬁcking of cargo
proteins to the ER Golgi Intermediate Compartment (ERGIC).
Kv11.1a proteins trafﬁc out of the ER in COPII vesicles, because
expressing a dominant-negative mutant of SAR1 prevents the ER
export of Kv11.1a proteins to the Golgi apparatus and cell mem-
brane [55].
In general, incompletely or misfolded proteins are retained in
the ER because they are excluded from ERES. This is because
incompletely or misfolded proteins interact with molecules in the
other parts of the ER to prevent them from entering ERES and/or
adaptor proteins in ERES selectively recruit only correctly folded
proteins to ERES for export in COPII vesicles [49]. Consistent with
the latter, Roti and colleagues identiﬁed a potential Kv11.1a
adaptor protein, the Golgin-associated vesicular transport GM130
[56]. Their data suggest that GM130 interacts with the COOH-
terminus of Kv11.1a and participates in the tethering and/or tar-
geting of Kv11.1a-containing vesicles within the Golgi apparatus.
Once Kv11.1a proteins trafﬁc to the Golgi apparatus, they are
terminally glycosylated to a 155 kDa glycoprotein [50]. The
majority of the 155 kDa Kv11.1a proteins in the cell reside in the
cell membrane because they are susceptible to extracellular pro-
tease digestion [57]. Many studies infer the trafﬁcking efﬁciency of
Kv11.1a or identify class 2 LQT2 mutations by using western blot
analysis to quantify the relative amount of the immature (135 kDa)
and mature (155 kDa) Kv11.1 proteins (Fig. 5).3. Molecular mechanism of class 2 LQT2 mutations
3.1. Class 2 LQT2 mutations
Class 2 LQT2-linked mutations decrease the folding efﬁciency
of Kv11.1a proteins and increase their degradation in the ERAD
pathway [44,58]. Some class 2 LQT2 proteins also activate ER stress
pathways [59]. Not surprisingly, cell culture conditions that sta-
bilize or facilitate the native folding of misfolded proteins can
increase the trafﬁcking and functional expression of most class
2 LQT2 proteins to the cell membrane (Fig. 5) [60,61]. Zhou and
colleagues (1999) were the ﬁrst to show that culturing cells at
lower incubation temperature (26 °C) or in drugs that bind to
Kv11.1a proteins and block IKr increase the cell membrane and
functional expression of certain class 2 LQT2 proteins (tempera-
ture or pharmacological correction, respectively; Fig. 5) [60].
Subsequent studies show that the trafﬁcking deﬁcient phenotypes
for many different class 2 LQT2 proteins undergo temperature and/
or pharmacological correction [28,62].
Fig. 5. A diagram of the Kv11.1 channel trafﬁcking pathway. KCNH2 is transcribed
and spliced to mRNA, which is then translated in the ER as a core glycosylated
Kv11.1a α-subunit with a molecular mass of 135 kDa. It undergoes terminal gly-
cosylation in the Golgi apparatus and its molecular mass increases to 155 kDa.
Shown are representative Western blots for cells expressing WT Kv11.1a proteins or
the class 2 LQT2 proteins harboring the G601S mutation. In control conditions, the
immunoblot of cells expressing WT Kv11.1a proteins contains both immature and
mature forms (top solid arrow), whereas cells expressing the Kv11.1a proteins with
the G601S mutation generate only the immature form (bottom solid arrow).
Incubating cells at 26 7̄C or in the IKr blocker E-4031 (E4) overnight increases the
mature form in cells expressing the Kv11.1 proteins with the G601S mutation
(dashed arrow).
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Initial studies of different LQT2 proteins were done using het-
erologous expression in Xenopus oocytes [20]. These studies pri-
marily focus on Kv11.1 channel gating and DN phenotypes
[20,23,63]. However, Furutani and colleagues [61] found that the
LQT2 mutation Gly601Ser (G601S) exhibits a large difference in
the LOF phenotype when expressed in oocytes vs. mammalian
cells. The reason for this discrepancy was unclear, but the authors
speculate that it was secondary to the differences in the incubation
temperatures of the different cells types. Zhou and colleagues
(1999) found that lowering the incubation temperature of mam-
malian cells from 37 °C to 26 °C increases the terminal glycosyla-
tion and functional expression of the class 2 LQT2 mutant protein
N470D [64]. Recently, Anderson and colleagues (2014) [28] per-
formed a comprehensive analysis of LQT2-linked missense muta-
tions and demonstrated a clear domain-dependence to tempera-
ture correction. Western blot analysis of cells expressing different
class 2 LQT2 proteins show that the protein trafﬁcking for 80% (40/
49) of the mutations in the PASD, 20% (12/60) of the mutations in
the pore domain, and 60% (15/24) of mutations in the CNBD
increases at lower incubation temperatures [28].
3.3. Pharmacological correction
Zhou and colleagues (1999) also showed that culturing cells in
IKr blockers (i.e. the class III anti-arrhythmic E-4031) improves the
trafﬁcking of some class 2 LQT2 proteins [60]. The amino acid
residues Y652 and F656 in S6 of the Kv11.1a α-subunit pore
domain are critical for the high-afﬁnity block of IKr [65,66]. Ficker
and colleagues (2002) found that pharmacological correction of
class 2 LQT2 proteins is strongly reduced when F656 was mutated
into a more hydrophilic cysteine [67]. Conversely, engineering
second site mutations at Y652 mitigates the trafﬁcking deﬁcient
class 2 LQT2 phenotype for several class 2 LQT2 proteins [68].
Taken together, these results demonstrate the signiﬁcance of
hydrophobic drug–pore interactions for increasing the trafﬁckingof class 2 LQT2 proteins and IKr block. Since these original reports,
dozens of different trafﬁcking deﬁcient LQT2 proteins are shown
to undergo pharmacological correction with IKr blockers [28].
Anderson and colleagues (2014) found that pharmacological cor-
rection also depends on the domain the mutation is located.
Western blot analyses of cells expressing class 2 LQT2 proteins
show that incubating cells in E-4031 causes pharmacological cor-
rection for 47% (23/49) of the mutations in the PASD, 33% (20/60)
of the mutations in the pore domain, and 21% (5/24) of the
mutations in the CNBD [28].
It remains to be seen if the drug–channel interactions that
improve the trafﬁcking of LQT2 proteins can be dissociated from
the interactions that mediate drug block of IKr. This would have
important implications as a potential therapeutic approach to
improve mutant Kv11.1a protein trafﬁcking in many LQT2 patients.
There are currently several drugs that appear to improve LQT2
protein trafﬁcking at drug concentrations much lower than the
drug concentration needed to block IKr. However, it is not clear
whether these drugs normalize the trafﬁcking of LQT2 proteins by
binding to the intracellular vestibule or via other unidentiﬁed
mechanisms [69,70]. These studies identify the potential for fur-
ther development and application of pharmacological correction
as a novel therapeutic approach in some patients/families
with LQT2.
3.4. Subclasses of class 2 mutations
It should be noted that the trafﬁcking or function of WT Kv11.1a
proteins is not improved by incubation at lower temperatures or in
the presence of drugs that cause temperature or pharmacological
correction of class 2 LQT2 proteins [60,62]. This suggests that
temperature and pharmacological correction speciﬁcally com-
pensate for mutation-speciﬁc changes in the native folding of
Kv11.1a proteins rather than simply increasing overall Kv11.1a
protein stability [68]. This is consistent with the mutation- and
domain-speciﬁc patterns of temperature and pharmacological
correction [28,71]. For example, several class 2 LQT2 mutations
located in the PASD and CNBD only undergo temperature correc-
tion, whereas none of the class 2 LQT2 mutations in the pore
domain only undergo temperature correction. All of the pore
domain mutations that undergo temperature correction also
undergo pharmacological correction. Additionally, several class
2 LQT2 mutations in the pore domain only undergo pharmacolo-
gical correction, but none of the class 2 LQT2 mutations in the
PASD and CNBD show pharmacological correction only. All of the
mutations in the PASD or CNBD that undergo pharmacological
correction also undergo temperature correction. These domain-
speciﬁc differences in correction suggest that temperature cor-
rection facilitates the folding of Kv11.1a proteins at multiple steps
in the biogenic pathway (i.e. assembly, formation of the voltage-
sensor/pore domains, increasing the proximity of the NH2 and
COOH termini, etc.), whereas pharmacological correction facil-
itates folding of Kv11.1a intermediates late in the biogenic pathway
(e.g., after the formation of the pore domain).
3.5. Chaperones interact with Kv11.1 channels affected by class
2 LQT2 mutations
Hsp90 is critical for folding and trafﬁcking of WT Kv11.1a pro-
teins. Therefore, it is not surprising that Hsp90 inﬂuences ER
retention and ERAD of Kv11.1a proteins affected by class 2 LQT2
mutations. Several different class 2 LQT2 proteins remain tightly
associated with Hsp90 and Hsp70 in the ER [44]. Temperature and
pharmacological correction cause class 2 LQT2 channel–chaperone
complexes to dissociate from one another. Iwai and colleagues
(2013) found that Hsp90 overexpression decreases the binding of
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increases the functionality of class 2 LQT2 mutant proteins that
harbor a frameshift mutation in the COOH-terminus [47]. Over-
expression of Hsp90 or the Hsp90 co-chaperone FKBP38 also
increases the trafﬁcking for several other class 2 LQT2 proteins
[45,72]. Together the data suggest that Hsp90 might limit ERAD,
stabilize Kv11.1a proteins, and facilitate the folding for certain class
2 LQT2 proteins.
The roles that Hsp40, Hsc70, and Hsp70 have on the trafﬁcking
of class 2 LQT2 proteins are less clear. Although expression of
Hsp40 decreases the trafﬁcking of WT Kv11.1a proteins in cells
incubated at physiological temperature, expression of Hsp40 does
not negatively affect WT Kv11.1a protein trafﬁcking at lower
incubation temperatures [48]. However, the expression of Hsp40
inhibits the temperature correction of class 2 LQT2 proteins with
the G601S mutation. This means that subtle structural differences
likely still exist between WT and some class 2 LQT2 proteins, even
when cells are incubated at temperatures that promote correction.
Li and colleagues (2011) found that the degree of Hsc70 associa-
tion with different class 2 LQT2 proteins depends on the topolo-
gical location of the mutation [43]. The level of Hsc70-associated is
higher for class 2 LQT2 mutations located in cytosolic domains (i.e.
NH2 and COOH termini). Additionally, they found that heat
shocking the cells (to increase Hsp70 expression) preferentially
promotes the maturation of class 2 LQT2 proteins. These data raise
the possibility that limiting the association of Hsc70 with Kv11.1a
might have therapeutic potential for class 2 LQT2 mutations in
cytosolic domains.
3.6. Sequestration of proteins affected by class 2 LQT2 mutations
Immunocytochemistry studies show that class 2 LQT2 channels
are selectively stored in a microtubule-dependent ER compart-
ment that colocalizes with the transitional ER marker BAP31 (but
not the perinuclear ER marker calnexin; the ERAD domain marker
Derlin; the ERES marker Sec31; or the ERGIC marker ERGIC-53)
[73,74]. Studies show that incubating cells in brefeldin A (bfa, a
fungal metabolite that inhibits the retrograde transport of proteins
to the ER) and the microtubule depolymerizing agent nocodazole
blocks ER export and causes export cargo to accumulate in large
spherical or dilated ERES easily visualized using microscopy
[73,75]. Treating cells expressing class 2 LQT2 proteins in bfa and
nocodazole conﬁrms that they are excluded from the ERES.
Interestingly, Roti and colleagues (2002) show that several class
2 LQT2 proteins do not to bind to GM130 [56]. These data provide
a working model whereby some class 2 LQT2 proteins are stored in
a transitional ER compartment and excluded from ERES because
they fail to associate with the putative Kv11.1a adapter GM130.
Studies show that pharmacological correction directly increa-
ses the trafﬁcking of class 2 LQT2 proteins stored in the transi-
tional ER compartment [60,74]. These ﬁndings are surprising
because they suggest that a steady-state pool of class 2 LQT2
proteins exist in the ER that are not yet targeted for ERAD. The
implications are that cells can be brieﬂy incubated in IKr blockers
to increase the functional expression of class 2 LQT2 proteins
sequestered in the ER. Once the class 2 LQT2 proteins trafﬁc to the
membrane, they remain functionally active for several hours after
the drug has been washed out [74]. These data provide an
important proof of principle that IKr blockers can be acutely
administered to cause pharmacological correction of class 2 LQT2
proteins and increase IKr.
3.7. Patient-speciﬁc cellular models for class 2 LQT2
The ability to generate inducible pluripotent stem cell derived
cardiomyocytes (iPSC-CMs) offers a new cellular platform foridentifying patient-speciﬁc molecular mechanisms of LQT2 and
developing personalized drug therapy [76]. Itzhaki and colleagues
(2011) were ﬁrst to obtain an iPSC line from a patient with the
class 2 LQT2 missense mutation A614V [77]. The LQT2-patient
derived iPSC-CMs show a signiﬁcant prolongation of the AP,
smaller IKr, marked arrhythmogenicity, early afterdepolarizations
(EADs), and triggered arrhythmias [77]. Importantly, the authors
were able to use the cells to evaluate the potency of several
pharmacological agents that worsened or mitigated the cellular
LQT2 phenotype.
Bellin and colleagues (2013) developed patient-derived iPSC-
CMs from a patient with the class 2 LQT2 mutation N996I [78].
They used targeted gene correction of the N996I allele to restore
IKr density and normalize AP duration in this iPSC-CM line.
Moreover, introducing the same mutation into human embryonic
stem cells (hESCs) result in the development an electro-
physiological phenotype similar to the one detected in iPSC-CMs
from the patient. These data demonstrate that genetic modiﬁca-
tion of iPSC-CMs and hESC can clearly delineate the pathogenic
cause underlying a patient's disease phenotype with a suspected
LQTS-causing mutation.
Matsa and colleagues studied iPSC-CMs derived from a
patient with the DN class 2 LQT2 mutation A561T [79]. They
conﬁrmed the class 2 phenotype in iPSC-CMs and used allele-
speciﬁc RNA interference (RNAi) to selectively degrade mutant
mRNA while leaving WT mRNA intact. Treating the LQT2 iPSC-
CMs with the mutation-speciﬁc siRNA normalized the AP
duration, increased IKr, and decreased the frequency EADs. More
recently, Mehta and colleagues (2014) studied iPSC-CMs derived
from a patient with the related class 2 LQT2 mutation A561V
[80]. They examined the relative expression of the A561V and
WT alleles and found that the A561V allele is expressed at a
higher level than the WT allele. Furthermore, they found that
several quality control genes including cysteine proteases,
Hsp90, Hsp70, and ubiquitin are up regulated in LQT2 iPSC-CMs
compared to their levels in control cells. In an attempt to correct
the class 2 LQT2 phenotype, the investigators incubated
LQT2 iPSC-CMs with ALLN (N-[N-(N-acetyl-L-leucyl)-L-leucyl]-L-
norleucine), a calpain/proteasome inhibitor. ALLN incubation
decreases the expression of several of the calpains, Hsp70, and
ubiquitin genes, but increases the expression of Hsp90. Impor-
tantly, ALLN incubation increases the trafﬁcking of the Kv11.1a
proteins, increases IKr, and decreases the AP duration in the
LQT2 iPSC-CMs.4. Conclusions
4.1. Summary
LQT2 is the second most common type of Romano Ward LQTS.
It is caused by mutations in KCNH2 that primarily decrease the
number of IKr channels in the cell membrane by disrupting
channel synthesis (class 1 mechanism) or their trafﬁcking (class
2 mechanism). Functional IKr channels in cardiac cells are gener-
ated by the co-assembly of Kv11.1a/Kv11.1b α-subunits and the
auxiliary Kþ channel subunit MiRP. The folding and ER export of
Kv11.1a is dependent on Hsp90, and the stability/ERAD of Kv11.1a
is regulated by its interactions with Hsp40, Hsp/c70 and the E3
ligase CHIP. Studies suggest that Kv11.1a is exported from the ER in
COPII vesicles and its trafﬁcking early in the secretory pathway is
inﬂuenced by the putative adaptor protein GM130. Class 2 LQT2
mutations primarily occur in the PASD, pore domain, or CNBD.
Incubating cells at reduced temperatures or in drugs that bind
Kv11.1a and block IKr can correct the trafﬁcking for many different
class 2 LQT2 proteins. Some of these mutated proteins are
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compartment prior to being degraded via ERAD. The class 2 LQT2
mechanism has been veriﬁed in iPSC-CMs from a small number of
different LQT2 patients. These studies show that targeted gene
correction of the LQT2 mutation, siRNA knock down of the mutant
mRNA, or incubating cells in drugs that inhibit calpain/proteasome
degradation mitigates the LQT2 patient iPSC-CM cellular
phenotypes.
4.2. In memoriam of Dr. Eckhard Ficker
Dr. Eckhard Ficker, one of the pioneers of Kv11.1 channel stu-
dies, passed away suddenly in 2013. He was the ﬁrst to describe
subclasses of class 2 LQT2 mutations [71], the role of Kv11.1a
binding domain for pharmacological correction [67], and the reg-
ulation of Kv11.1a trafﬁcking by Hsp90/Hsp70 [44]. He made sev-
eral other seminal discoveries related to Kv11.1a channels [81–88].
Eckhard's work was always innovative and he was very helpful to
many investigators. He will be sadly missed.Conﬂict of interest
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